pharmaceutical daily news

Foamix Pharmaceuticals showed its topline results of its third Phase 3 clinical trial (FX2017-22) of FMX101 for the treatment of moderate-to-severe acne.

PureTech Health and its affiliate Karuna have completed a $42 million Series A financing round, which will be used to advance its lead product candidate, KarXT (Karuna-xanomeline-trospium chloride), including the a Phase 2 trial in patients with schizophrenia in the third quarter of 2018 and the expansion into other therapeutic areas,

Amryt ensure US Food and Drug Administration’s grant a Rare Pediatric Disease designation for its lead development asset AP101, for the treatment of Epidermolysis Bullosa (“EB”).

Sanofi reported €762m of net income in the second quarter 2018, after net sales of €8,176 million, down 5.7% on a reported basis.

4D pharma showed that specific single bacterial strains from the human gut microbiota can serve as therapeutic inhibitors of the human enzyme histone deacetylase (HDAC), which is particularly relevant for disease areas involving host epigenetic aberrations.

Beximco Pharmaceuticals got approval from the US Food and Drug Administration (FDA), for its Nadolol tablets, a generic equivalent of Bristol-Myers Squibb’s Corgard, for hypertension and chest pain, angina pectoris. 

Apricus Biosciences will merge with Seelos Therapeutics, Inc., a privately-held biotechnology company, in an all-stock transaction, it announced on Monday, and will focus on bringing to shelves central nervous system (CNS) therapeutics.

Destiny Pharma’s first of two Phase 1 safety clinical studies of testing XF-73’s potential to cause dermal irritation, as Destiny’s lead candidate for the prevention of post-surgical staphylococcal infections, brought good news with positive results, which support the potential of XF compounds in dermal infection indications and also reinforce the target